PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas

International Journal of Cancer

Volumn 89, Issue 6, 2000, Pages 535-536

  Knecht, Rainald ^a   Oberhauser, Christine ^a   Strebhardt, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PHOSPHOTRANSFERASE;

CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; LETTER; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; FEMALE; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034693687     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001120)89:6<535::AID-IJC12>3.0.CO;2-E     Document Type: Letter

References (6)

1. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the heart and neck: A Southwest Oncology Group study
2. Inductiondownregulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors
3. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck
4. Cell-cycle control: Polo-like kinases join the outer circle
5. Significance of p53, PCNA and Ki67 in the prognosis of squamous cell carcinoma of the oral cavity
6. Prognostic significance of polo-like kinase (PLK) expression in non-small-cell lung cancer